Scrip’s Rough Guide To Targeted Protein Degradation
Drugging The Undruggable
Executive Summary
By hijacking a process that cells use to keep themselves shipshape, targeted protein degradation has become a hot new area of drug development. Scrip takes an in-depth look at the field ahead of a wave of data expected this year from early candidates that will give some insight into whether this strategy will truly open a new way to combat disease.
You may also be interested in...
Can China Innovate? Degron Aims For First-In-Class TPD Therapies
Fresh out of an impressive new round of financing and armed with $32m, Shanghai's Degron Therapeutics is aiming for nothing but first-in-class treatments. Its co-founder and CSO shares views on creating original innovative drugs from inside China in an exclusive interview with Scrip.
Proteome-Focused ProFound Emerges From Flagship Pioneering
The company says its platform technology has uncovered “tens of thousands” of previously undiscovered proteins.
Ups And Downs In Protein Degraders: Big Deals For BMS, Merck KGaA, Safety Worries For Kymera
Kymera has seen its share price fall more than 30% this week as investors struggle to gauge how much future market potential targeted protein degraders will have.